Literature DB >> 34956452

Identification and preliminary validation of a four-gene signature to predict metastasis and survival in osteosarcoma.

Yiming Zhang1, Xuan Lei1, Rong He2, Lianghao Mao1, Pan Jiang1,3, Chenlie Ni1, Xinyu Zhong1, Zhengyu Yin1, Xuan Wu4, Dapeng Li1, Qiping Zheng4,5.   

Abstract

Osteosarcoma is a primary malignant bone tumor that occurs frequently in children and adolescents and has a propensity for drug resistance, recurrence, and metastasis. The purpose of this study was to identify potential target genes to predict metastasis and survival in patients with osteosarcoma. We analyzed gene expression profiles and corresponding clinical data of patients with osteosarcoma in the Gene Expression Omnibus database and identified 202 genes that were differentially expressed between osteosarcoma cells and normal osteoblasts. Univariate and multivariable Cox regression analyses identified four risk genes that affected osteosarcoma prognosis: MCAM, ENPEP, LRRC1, and CPE. Independent prognostic analyses and clinical correlation studies showed that the four risk genes constituted an independent prognostic signature that correlated with survival and clinical parameters including age and distant metastasis. In a single-sample Gene Set Enrichment Analysis, risk scores based on the prognostic signature correlated with tumor infiltration by immune cells and immune functions in osteosarcoma. A subsequent analysis showed that the expression levels of the four genes in the prognostic signature were predictive of overall survival and metastasis-free survival of patients with osteosarcoma. Furthermore, Human Cancer Metastasis Database and qRT-PCR analyses demonstrated that the four risk genes are overexpressed in osteosarcoma tissues and cell lines. In summary, we developed and validated a four-gene prognostic signature that may be useful in osteosarcoma diagnosis and metastasis prediction. AJTR
Copyright © 2021.

Entities:  

Keywords:  Osteosarcoma; bioinformatic analysis; metastasis; prognosis; survival analysis

Year:  2021        PMID: 34956452      PMCID: PMC8661158     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  43 in total

Review 1.  Osteosarcoma.

Authors:  J Ritter; S S Bielack
Journal:  Ann Oncol       Date:  2010-10       Impact factor: 32.976

Review 2.  Targeting RAS signalling pathways in cancer therapy.

Authors:  Julian Downward
Journal:  Nat Rev Cancer       Date:  2003-01       Impact factor: 60.716

3.  Silencing of carboxypeptidase E inhibits cell proliferation, tumorigenicity, and metastasis of osteosarcoma cells.

Authors:  Shuli Fan; Xu Li; Leiming Li; Liguo Wang; Zhangzhen Du; Yan Yang; Jiansong Zhao; Yan Li
Journal:  Onco Targets Ther       Date:  2016-05-10       Impact factor: 4.147

4.  Sodium cantharidate targets STAT3 and abrogates EGFR inhibitor resistance in osteosarcoma.

Authors:  Xiang Lu Ji; Ming He
Journal:  Aging (Albany NY)       Date:  2019-08-15       Impact factor: 5.682

5.  The SCRIB Paralog LANO/LRRC1 Regulates Breast Cancer Stem Cell Fate through WNT/β-Catenin Signaling.

Authors:  Leonor Lopez Almeida; Michael Sebbagh; François Bertucci; Pascal Finetti; Julien Wicinski; Sylvie Marchetto; Rémy Castellano; Emmanuelle Josselin; Emmanuelle Charafe-Jauffret; Christophe Ginestier; Jean-Paul Borg; Marie-Josée Santoni
Journal:  Stem Cell Reports       Date:  2018-10-18       Impact factor: 7.765

6.  CircECE1 activates energy metabolism in osteosarcoma by stabilizing c-Myc.

Authors:  Shuying Shen; Teng Yao; Yining Xu; Deguang Zhang; Shunwu Fan; Jianjun Ma
Journal:  Mol Cancer       Date:  2020-10-26       Impact factor: 27.401

7.  Bone marrow mesenchymal stem cells-derived exosomal microRNA-193a reduces cisplatin resistance of non-small cell lung cancer cells via targeting LRRC1.

Authors:  Hongbo Wu; Xiaoqian Mu; Lei Liu; Huijuan Wu; Xiufeng Hu; Lijuan Chen; Jie Liu; Yu Mu; Fangfang Yuan; Wenjing Liu; Yanqiu Zhao
Journal:  Cell Death Dis       Date:  2020-09-25       Impact factor: 8.469

8.  Loss of p53 in mesenchymal stem cells promotes alteration of bone remodeling through negative regulation of osteoprotegerin.

Authors:  Tania Velletri; Yin Huang; Yu Wang; Qing Li; Mingyuan Hu; Ningxia Xie; Qian Yang; Xiaodong Chen; Qing Chen; Peishun Shou; Yurun Gan; Eleonora Candi; Margherita Annicchiarico-Petruzzelli; Massimiliano Agostini; Huilin Yang; Gerry Melino; Yufang Shi; Ying Wang
Journal:  Cell Death Differ       Date:  2020-07-21       Impact factor: 15.828

9.  MIR205 host gene (MIR205HG) drives osteosarcoma metastasis via regulating the microRNA 2114-3p (miR-2114-3p)/twist family bHLH transcription factor 2 (TWIST2) axis.

Authors:  Xin Wang; Xiaojie Yu; Xiongwu Long; Qianqian Pu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.